» Articles » PMID: 24200492

Expression Profile of Osteoprotegerin, RANK and RANKL Genes in the Femoral Head of Patients with Avascular Necrosis

Overview
Journal Exp Mol Pathol
Publisher Elsevier
Date 2013 Nov 9
PMID 24200492
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Femoral head avascular necrosis (AVN) is a recalcitrant disease of the hip that leads to joint destruction. Osteoprotegerin (OPG), Receptor Activator of Nuclear Factor kappa-B (RANK) and RANK ligand (RANKL) regulate the balance between osteoclasts-osteoblasts. The expression of these genes affects the maturation and function of osteoblasts-osteoclasts and bone remodeling. In this study, we investigated the molecular pathways leading to AVN by studying the expression profile of OPG, RANK and RANKL genes.

Material And Methods: Quantitative Real Time-PCR was performed for evaluation of OPG, RANK and RANKL expression. Analysis was based on parallel evaluation of mRNA and protein levels in normal/necrotic sites of 42 osteonecrotic femoral heads (FHs). OPG and RANKL protein levels were estimated by western blotting.

Results: The OPG mRNA levels were higher (insignificantly) in the necrotic than the normal site (p > 0.05). Although the expression of RANK and RANKL was significantly lower than OPG in both sites, RANK and RANKL mRNA levels were higher in the necrotic part than the normal (p < 0.05). Protein levels of OPG and RANKL showed no remarkable divergence.

Conclusions: Our results indicate that differential expression mechanisms for OPG, RANK and RANKL that could play an important role in the progress of bone remodeling in the necrotic area, disturbing bone homeostasis. This finding may have an effect on the resulting bone destruction and the subsequent collapse of the hip joint.

Citing Articles

Is core decompression and bone marrow concentrate with demineralized bone matrix and platelet-rich fibrin suitable for treating femoral head osteonecrosis?.

Cevolani L, Focaccia M, Spazzoli B, Bruschi A, Staals E, Dozza B J Hip Preserv Surg. 2025; 11(4):263-270.

PMID: 39839553 PMC: 11744473. DOI: 10.1093/jhps/hnae031.


Clinical Characteristics, Current Treatment Options, Potential Mechanisms, Biomarkers, and Therapeutic Targets in Avascular Necrosis of Femoral Head.

Khanchandani P, Narayanan A, Naik A, Kannan V, Pradhan S, Srimadh Bhagavatham S Med Princ Pract. 2024; 33(6):519-536.

PMID: 39168116 PMC: 11631174. DOI: 10.1159/000541044.


The use of hyperbaric oxygen for avascular necrosis of the femoral head and femoral condyle: a single centre's experience over 30 years.

Currie J, Gawthrope I, Banham N Diving Hyperb Med. 2024; 54(2):92-96.

PMID: 38870950 PMC: 11444917. DOI: 10.28920/dhm54.2.92-96.


The protective role of vitamins C and E in steroid-induced femoral head osteonecrosis: An experimental study in rats.

Beytemur O, Dasci M, Gok Yurttas A, Yaprak Bayrak B, Alagoz E Jt Dis Relat Surg. 2023; 35(1):72-84.

PMID: 38108168 PMC: 10746895. DOI: 10.52312/jdrs.2023.1405.


Decreased serum MMP-9 levels in patients with nontraumatic osteonecrosis of the femoral head.

Li G, Ji F, Guo W, Wei B BMC Musculoskelet Disord. 2023; 24(1):240.

PMID: 36991363 PMC: 10053116. DOI: 10.1186/s12891-023-06342-9.